We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The Company is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across mu... Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The Company is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. Its selected TIL approach focuses on selecting and expanding potent tumor-reactive T cells to overcome the limitations of bulk TILs. Its pipeline includes TIDAL-01 and TIDAL-02. Its lead selected TIL product candidate, TIDAL-01, utilizes an unbiased identification and functional screening process to isolate and selectively expand the breadth of tumor-reactive TILs from the patient¿s tumor. Its next selected TIL program, TIDAL-02, is being designed to encompass a streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function. Show more
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund...
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily...
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1808 | -21.5238095238 | 0.84 | 0.8462 | 0.5699 | 305745 | 0.73490308 | CS |
4 | -2.0008 | -75.2180451128 | 2.66 | 3.05 | 0.5699 | 263438 | 1.16102101 | CS |
12 | -2.2408 | -77.2689655172 | 2.9 | 3.8782 | 0.5699 | 205819 | 1.91678981 | CS |
26 | -4.7208 | -87.7472118959 | 5.38 | 6.005 | 0.5699 | 162830 | 2.35236853 | CS |
52 | -10.7408 | -94.2175438596 | 11.4 | 13.2 | 0.5699 | 151428 | 2.88099106 | CS |
156 | -10.7408 | -94.2175438596 | 11.4 | 13.2 | 0.5699 | 151428 | 2.88099106 | CS |
260 | 0 | 0 | 0 | 0.7 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions